

## News Releases

[Register for email alerts.](#)

All Categories

### Archive



---

**Date** 12/20/13

**Title**

Valeant Pharmaceuticals To Present At Industry Conferences

**Download**

[PDF](#)

---

**Date** 12/16/13

**Title**

Valeant Pharmaceuticals Agrees to Acquire Solta Medical for \$2.92 Per Share in Cash

**Download**

[PDF](#)

---

**Date** 12/13/13

**Title**

Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance

**Download**

[PDF](#)

---

**Date** 12/02/13

**Title**

Valeant Pharmaceuticals Announces Redemption Of The Remaining \$465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016

**Download**

[PDF](#)

---

**Date** 11/25/13

**Title**

Valeant Pharmaceuticals Announces New Management Appointment

**Download**[PDF](#)**Date**

11/15/13

**Title**

Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes

**Download**[PDF](#)**Date**

11/15/13

**Title**

Valeant Pharmaceuticals Announced Redemption Of \$450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016

**Download**[PDF](#)**Date**

11/15/13

**Title**

Valeant Pharmaceuticals Announces U.S. Approval Of Luzu® Cream, 1%

**Download**[PDF](#)**Date**

11/15/13

**Title**

Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes

**Download**[PDF](#)**Date**

10/31/13

**Title**

Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results

**Download**[PDF](#)**Date**

10/28/13

**Title**

Valeant Pharmaceuticals Announces Settlement Agreement With Anacor

**Download**

**PDF**

---

**Date** 10/18/13

**Title**

Valeant Pharmaceuticals Announces Award In Anacor Dispute

**Download**

**PDF**

---

**Date** 10/08/13

**Title**

Valeant Pharmaceuticals To Announce 2013 Third Quarter Results On October 31, 2013

**Download**

**PDF**

---

**Date** 10/03/13

**Title**

Valeant Pharmaceuticals Announces Approval Of Jublia® For The Treatment Of Onychomycosis In Canada

**Download**

**PDF**

---

**Date** 10/03/13

**Title**

Valeant Pharmaceuticals' Bausch + Lomb Receives U.S. FDA Clearance For Novel Monthly Disposable Contact Lens

**Download**

**PDF**

---

**Date** 10/02/13

**Title**

Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence

**Download**

**PDF**

---

**Date** 08/09/13

**Title**

Valeant Pharmaceuticals Announces Continuance

**Download**

**PDF**

**Date** 08/07/13

**Title**

Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results

**Download**

**PDF**

---

**Date** 08/06/13

**Title**

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb

**Download**

**PDF**

---

**Date** 07/15/13

**Title**

Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013

**Download**

**PDF**

---

**Date** 07/02/13

**Title**

Medicis Announces Five-Year Aesthetic Collaboration with Mentor

**Download**

**PDF**

---

**Date** 06/27/13

**Title**

Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes

**Download**

**PDF**

---

**Date** 06/24/13

**Title**

Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares

**Download**

**PDF**

---

**Date** 06/20/13

**Title**

Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option

**Download**

**PDF**

---

**Date** 06/18/13

**Title**

Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes

**Download**

**PDF**

---

**Date** 06/18/13

**Title**

Valeant Pharmaceuticals Prices Public Offering Of Common Shares

**Download**

**PDF**

---

**Date** 06/17/13

**Title**

Valeant Pharmaceuticals Announces Public Offering Of Common Shares

**Download**

**PDF**

---

**Date** 06/07/13

**Title**

Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus

**Download**

**PDF**

---

**Date** 05/28/13

**Title**

Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole

**Download**

**PDF**

---

**Date** 05/27/13

**Title**

Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For \$8.7 Billion

**Download**

**PDF**

---

**Date** 05/21/13

**Title**

Valeant Pharmaceuticals Announces 2013 Annual Meeting Results

**Download**

**PDF**

---

**Date** 05/20/13

**Title**

Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference

**Download**

**PDF**

---

**Date** 05/15/13

**Title**

Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors

**Download**

**PDF**

---

**Date** 05/13/13

**Title**

Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders

**Download**

**PDF**

---

**Date** 05/10/13

**Title**

Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal

**Download**

**PDF**

---

**Date** 05/02/13

**Title**

Valeant Pharmaceuticals Provides Efinconazole Update

**Download**

**PDF**

---

**Date** 05/02/13

**Title**

Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results

**Download****PDF****Date**

05/01/13

**Title**

Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel

**Download****PDF****Date**

04/25/13

**Title**

Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc.

**Download****PDF****Date**

04/24/13

**Title**

Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc.

**Download****PDF****Date**

04/23/13

**Title**

Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.

**Download****PDF****Date**

04/22/13

**Title**

Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc.

**Download****PDF****Date**

04/16/13

**Title**

Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013

**Download****PDF****Date**

04/10/13

**Title**

Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara®

**Download****PDF****Date**

04/05/13

**Title**

Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape

**Download****PDF****Date**

04/04/13

**Title**

Valeant Pharmaceuticals Provides Update to Recent Event

**Download****PDF****Date**

04/03/13

**Title**

Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of \$24.00 Per Share In Cash

**Download****PDF****Date**

03/29/13

**Title**

Valeant Pharmaceuticals Announces Private Exchange Offer

**Download****PDF****Date**

03/20/13

**Title**

Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for \$19.75 Per Share in Cash

**Download****PDF****Date**

02/28/13

**Title**

Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results

**Download****PDF****Date**

02/21/13

**Title**

Valeant Pharmaceuticals Acquires U.S. Rights to Targretin® from Eisai Inc.

**Download****PDF****Date**

02/01/13

**Title**

Valeant Completes Acquisition Of Natur Produkt In Russia

**Download****PDF****Date**

01/31/13

**Title**

Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013

**Download****PDF****Date**

01/03/13

**Title**

Valeant Pharmaceuticals Announces New Management Appointment

**Download****PDF****Date**

01/02/13

**Title**

Valeant Pharmaceuticals To Present At 31st Annual J.P. Morgan Healthcare Conference

**Investor Inquiries**[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642

514-856-3855 (Canada)

[LEGAL NOTICE](#)[PRIVACY POLICY](#)[EMAIL ALERTS](#)[EMAIL PAGE](#)[RSS FEED](#)

Use of this site signifies your agreement to  
the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights  
reserved. MTB.0230.USA.18 V2.0

**Media inquiries**[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

908-569-3692

**CALIFORNIA RESIDENTS: DO NOT SELL MY  
PERSONAL INFORMATION**